Twist生物科学公司报告,EPS Q2误差,超过收入估计数,并提出了2024财政年度的指导意见。 Twist Bioscience reported Q2 EPS miss, exceeded revenue estimates, and raised FY 2024 guidance.

Twist Bioscience（TWST）公布第二季度收益，每股收益为（$1.47），而市场预期为（$0.76），但营收为$81.5M，超出预期。 Twist Bioscience (TWST) reported a Q2 earnings miss with EPS of ($1.47) vs. consensus estimate of ($0.76), but revenue of $81.5M exceeded estimates. 该公司更新了2024财政年度EPS指南和Q4 2024指南。 The company updated its FY 2024 guidance for EPS and Q4 2024 guidance. 尽管收入亏损,但NASDAQ:TWST股票交易额达2.36美元,达到45.33美元。 Despite the earnings miss, NASDAQ:TWST stock traded up $2.36, reaching $45.33. 过去90天内幕出售了11 289股股票。 Insiders have sold 11,289 shares in the past 90 days. JP摩根、Evercore、斯科舍银行、Guggenheim和TD Cowen的分析员提供了最新价格指标和评级。 Analysts at JPMorgan, Evercore, Scotiabank, Guggenheim, and TD Cowen provided updated price targets and ratings. 制造和销售合成DNA制品的Twist生物科学公司收入逐年增长27.7%。 Twist Bioscience Corporation, which manufactures and sells synthetic DNA-based products, saw its revenue increase by 27.7% year-over-year.